Jagsonpal Pharmaceuticals Ltd

AI

Jagsonpal Pharmaceuticals Ltd

₹ 210 1.03%
19 Nov - close price
About

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Key Points

Business Overview and Market Reach:[1][2]
JPL is a 100% India-focused, asset-light branded-generics pharmaceutical company
with a legacy dating back to 1964. Its key therapy areas include Gynaecology, Orthopaedics, Dermatology, Wellness and Critical Care. It reaches 1,37,000+ doctors and 1,000+ hospitals. Gynaecology remains its largest franchise, engaging around 35,000 of India's 39,000 gynaecologists and holding a #7 CVM rank. Orthopaedics is the second-largest pillar, with a #2 CVM rank and approximately 80% doctor coverage.

  • Market Cap ₹ 1,390 Cr.
  • Current Price ₹ 210
  • High / Low ₹ 265 / 155
  • Stock P/E
  • Book Value ₹ 36.4
  • Dividend Yield 1.90 %
  • ROCE %
  • ROE %
  • Face Value ₹ 2.00

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 5.78 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026
58 47 43 61 75 74 59 76 74 73 64 82 96
49 44 41 51 58 58 50 61 58 57 53 65 79
Operating Profit 8 3 3 10 16 16 9 14 16 16 11 17 17
OPM % 14% 7% 6% 17% 22% 21% 15% 19% 22% 22% 17% 21% 18%
2 3 2 -2 2 26 3 3 3 1 3 3 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 1 2 2 2 2 2 2 2 2 2
Profit before tax 10 5 5 7 15 39 9 14 17 15 12 18 16
Tax % 25% 25% 22% 25% 25% 17% 24% 25% 25% 25% 25% 25% 25%
7 4 4 5 11 32 7 11 13 11 9 13 12
EPS in Rs 1.14 0.60 0.54 0.81 1.73 4.82 0.99 1.62 1.89 1.64 1.31 2.00 1.86
Raw PDF

(S): Standalone figures, shown where consolidated figures are not available.

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
138 143 144 127 167 159 188 218 237 209 269 287
129 132 138 138 157 150 169 192 203 186 218 229
Operating Profit 9 12 6 -11 9 9 19 26 34 23 51 58
OPM % 6% 8% 4.0% -9% 6% 5% 10% 12% 14% 11% 19% 20%
0 1 13 0 1 3 4 3 2 9 28 10
Interest 4 5 3 1 1 1 1 0 0 1 1 1
Depreciation 3 3 2 0 1 1 1 2 1 2 8 9
Profit before tax 2 4 14 -12 9 9 22 27 35 30 70 58
Tax % 30% 20% 18% -1% 20% 16% 22% 29% 23% 25% 21% 25%
1 3 12 -12 7 8 17 19 27 22 55 43
EPS in Rs 0.18 0.50 1.81 -1.76 1.10 1.20 2.60 2.88 4.08 3.40 8.34 6.43
Dividend Payout % 22% 8% 2% -2% 9% 17% 15% 56% 49% 59% 30% 62%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: 34%
5 Years: 28%
3 Years: 11%
1 Year: 2%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026
Equity Capital 13 13 13 13 13 13 13 13 13 13 13 13 13
Reserves 82 85 97 85 91 98 109 120 146 174 227 263 227
39 38 8 8 4 5 7 0 6 9 9 8 9
19 22 25 23 28 31 35 31 30 21 29 32 68
Total Liabilities 154 159 143 130 136 147 164 164 195 217 278 317 318
52 52 22 21 22 22 26 23 24 9 94 85 105
CWIP 0 0 0 3 4 4 0 0 0 0 0 0 0
Investments 0 0 0 0 0 11 15 51 1 0 0 0 0
102 108 121 105 110 109 123 91 170 208 184 231 213
Total Assets 154 159 143 130 136 147 164 164 195 217 278 317 318

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
4 9 -3 -2 31 11 28 7 47 35 55 47
-0 -2 41 -3 -1 -11 -2 -26 -58 -25 -45 -36
-1 -6 -34 -1 -6 -1 -7 -18 -0 -9 -12 -12
Net Cash Flow 2 1 5 -6 24 -0 19 -36 -11 2 -2 -1
Free Cash Flow 4 6 40 -5 30 12 28 6 48 35 90 47
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 53% 83% -6% 14% 311% 150% 164% 54% 158% 189% 124% 101%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Debtor Days 119 106 100 73 45 49 25 26 32 19 18 22
Inventory Days 176 246 295 307 164 191 134 122 82 68 58 51
Days Payable 42 60 56 54 59 76 82 76 66 35 37 40
Cash Conversion Cycle 252 292 339 325 150 164 77 72 48 53 39 33
Working Capital Days 68 72 154 149 67 55 32 59 34 52 9 11
ROCE % 5% 7% 3% -10% 9% 9% 18% 20% 25% 17% 23% 23%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Brands Ranked in Top 5 (Molecule Category)
Count

Log in to view insights

Please log in to see hidden values.

Login
Medical Representatives (Field Force)
Count
New Product Launches
Count (Annual)
Distributors/Stockists (Dealers)
Count
Doctors/Prescribers Covered
Count
Stocking Points
Count
MR Productivity (PCPM)
Rs Lakh per MR per month
Top 10 Brand Revenue Concentration
% of Revenue

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
68.48% 68.09% 68.04% 67.98% 67.82% 67.77% 67.65% 67.54% 67.39% 67.89% 69.06% 68.82%
0.53% 0.73% 1.10% 2.30% 2.10% 2.10% 2.17% 2.12% 2.12% 2.44% 2.30% 2.13%
0.82% 0.84% 0.84% 0.11% 0.00% 0.00% 0.05% 0.08% 0.15% 0.22% 0.62% 1.64%
30.16% 30.33% 30.01% 29.63% 30.10% 30.11% 30.12% 30.25% 30.34% 29.44% 28.04% 27.40%
No. of Shareholders 15,78516,28215,74815,63318,47121,08522,89924,65324,89526,26424,18126,537

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls